Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases (I to IV), Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2027
Instant Answers with GPT - Ask Now!
Ask real questions. Get complete answers !
Generating Response ...Updated on : May 22, 2023
The global clinical trial supplies market in terms of revenue was estimated to be worth $3.6 billion in 2022 and is poised to reach $5.7 billion by 2027, growing at a CAGR of 9.7% from 2023 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The updated financial information for each listed company is provided in a graphical representation in a single diagram (rather than multiple tables) in the new edition of the report until 2019 or 2022 (depending on availability). This would help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region or country, and business segment focus in terms of the highest revenue-generating segment. Market growth is largely driven by the growing R&D expenditure of pharmaceutical and biotechnology companies and the globalization of clinical trials.
Attractive Opportunities in the Clinical Trial Supplies Market
To know about the assumptions considered for the study, Request for Free Sample Report
Clinical Trial Supplies Market Dynamics
Driver: Increasing number of registered clinical trials
The number of registered clinical trials has increased significantly in recent years. As of September 18, 2022, there were over 4,28,103 clinical studies registered globally. Clinical trials have grown more complex in recent years and remain vital for the research and development of new drugs and products. Among all industry sectors, the pharmaceutical industry spends the largest percentage of their revenue on research and development.Data for the last ten years reveals a continuous growth in the number of registered and active clinical trial cases. This has led to a rise in outsourcing-related activities like material supplies, packaging, blinding, and delivery.
Restraint: High cost of drug development
Drug discovery and development involve huge costs due to the high attrition rate of drug candidates in development. Since Research and development for some of the rare diseases are very challenging and requires skilled labours to conduct clinical trials, drug research and development processes can be prone to failure.
Opportunity: Emerging Markets
North America and Europe, traditionally the major hubs for clinical trials, are facing challenges in terms of trial costs and patient pools. This has resulted in many cases of rare diseases and their clinical trials are being shifted to developing nations. Further, the technology and data are at the forefront of the clinical trial decision making. One of the top players in this market, Catalent, invested USD 9 million in a new clinical supply facility in San Diego to offer full clinical supply services for early-phase clinical trials. Biocair partnered with Linehaul Express in India to enhance its reach in these emerging markets. Marken (a subsidiary of UPS) acquired PCX International in Japan to enhance its footprint in the local market.
Challenge: The high cost of clinical trials is a major hindrance to the clinical trial supplies market growth
The high cost of clinical trials is a major challenge to the growth of global market. The rising costs of clinical trials are a great concern. Factors that contributes to the rising costs of clinical trials is the increasing need to collect more clinical data. This market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. Once a clinical trial has been given the go-ahead, research, and development (R&D) costs is very high.
The Oncology segment accounted for the largest segment in clinical trial supplies market
On the basis of therapeutic area, the market is divided into oncology, cardiovascular diseases, digestive disorders, CNS & mental disorders, immunology, blood disorders, infectious diseases, metabolic disorders, and other therapeutic areas (rare diseases, ENT diseases, Nephrology). In 2021, Oncology is the largest segment in this market. Factors such as high number of research studies on cancer therapeutics and the emerging markets focusing on bringing innovative cancer drugs into the market are driving the market in this segment.
The pharmaceutical and biotechnology companies segment accounted for the largest share in in clinical trial supplies market
On the basis of end users, the market is segmented into three segments—pharmaceutical & biotechnology companies, contract research organizations (CROs), and medical device companies. In 2021, the pharmaceutical and biotechnology companies accounted for the largest share of this market.
To know about the assumptions considered for the study, download the pdf brochure
North America was the largest region for global clinical trial supplies market
On the basis of region, the market is divided into North America, Europe, Asia Pacific, Rest of world. In 2021, North America accounted for the largest share of the global market, followed by Europe & Asia Pacific. The globalisation in clinical trials and significant investments in R&D for clinical trials in this region are major factors driving the growth of the North American market.
Key players in the Clinical trial supplies market include Thermo Fisher Scientific (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US).
Clinical Trial Supplies Market Report Scope:
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$3.6 billion |
|
Projected Revenue by 2027 |
$5.7 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 9.7% |
|
Market Drivers |
Increasing number of registered clinical trials |
|
Market Opportunity |
Emerging Markets |
This research report categorizes the clinical trial supplies market to forecast revenue and analyze trends in each of the following submarkets:
By Services
- Logistics & distribution
- Storage & retention
- Packaging, labeling, and blinding
- Manufacturing
- Comparator sourcing
- Other services (solutions, ancillary supply)
By phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- BA/ BE studies
By type
- Small-molecules
- Biologic drugs
- Medical devices
By therapeutic area
- Oncology
- CNS and mental disorders
- Cardiovascular diseases
- Digestive disorders
- Infectious diseases
- Metabolic disorders
- Immunology
- Blood disorders
- Other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology)
By end user
- Pharmaceutical & Biotechnology companies
- Contract Research Organisations (CROs)
- Medical Devices Companies
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Switzerland
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Rest of Asia Pacific (RoAPAC)
-
Rest of the World (RoW)
- Latin America
- Middlle East and Africa
Recent Developments
- In February 2022, Thermo Fisher entered into a partnership with Medidata to optimize clinical research site selection and speed up patient enrollment in clinical trials.
- In April 2021, Catalent added cryogenic capabilities at its Philadelphia clinical supply services facility. This expansion helped increase Catalent’s capabilities in gene therapies, packaging, labeling, and distribution of cryogenic materials for clinical trials.
- In April 2021, Parexel collaborated with Veeva Systems to improve their clinical processes for clinical trial delivery and enhance Veeva’s cloud technology.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global clinical trial supplies market?
The global clinical trial supplies market boasts a total revenue value of $5.7 billion by 2027.
What is the estimated growth rate (CAGR) of the global clinical trial supplies market?
The global clinical trial supplies market has an estimated compound annual growth rate (CAGR) of 9.7% and a revenue size in the region of $3.6 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 32)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1GLOBAL MARKET: GEOGRAPHIC SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
FIGURE 4 DATA TRIANGULATION METHODOLOGY
2.3 MARKET ESTIMATION METHODOLOGY
FIGURE 5 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS
FIGURE 6 GLOBAL MARKET: FINAL MARKET SIZE (USD BILLION)
2.4 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
FIGURE 8 FINAL CAGR PROJECTIONS (2022−2027)
2.5 INSIGHTS FROM PRIMARIES
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. - 46)
FIGURE 10 GLOBAL MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 GLOBAL MARKET SHARE, BY SERVICE, 2021
FIGURE 12 GLOBAL MARKET, BY PHASE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GLOBAL MARKET SHARE, BY THERAPEUTIC AREA, 2021
FIGURE 14 GLOBAL MARKET SHARE, BY END USER, 2021
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 50)
4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
FIGURE 16 INCREASING R&D EXPENDITURE OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
4.2 NORTH AMERICA: MARKET SHARE, BY TYPE AND COUNTRY (2021)
FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF GLOBAL MARKET IN NORTH AMERICA
4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN GLOBAL MARKET FROM 2022 TO 2027
5 MARKET OVERVIEW (Page No. - 53)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 GLOBAL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.3 IMPACT ANALYSIS
5.3.1 DRIVERS
5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies
5.3.1.2 Increasing number of registered clinical trials
FIGURE 20 REGISTERED CLINICAL STUDIES, 2011–2022
5.3.1.3 Increasing decentralization of clinical trials
5.3.2 RESTRAINTS
5.3.2.1 High cost of drug development
5.3.3 OPPORTUNITIES
5.3.3.1 Emerging markets
5.3.4 CHALLENGES
5.3.4.1 High cost of clinical trials
5.4 RANGES/SCENARIOS
FIGURE 21 SCENARIOS OF GLOBAL MARKET
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.6 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS OF GLOBAL MARKET
5.7 ECOSYSTEM/MARKET MAP
5.8 SUPPLY CHAIN
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: GLOBAL MARKET
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 DEGREE OF COMPETITION
5.10 REGULATORY LANDSCAPE
5.10.1 INTRODUCTION
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 3 GLOBAL MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.12 TECHNOLOGY ANALYSIS
5.12.1 INTERACTIVE RESPONSE TECHNOLOGY (IRT)
5.13 PATENT ANALYSIS
FIGURE 23 TOP PATENTS IN GLOBAL MARKET
6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE (Page No. - 69)
6.1 INTRODUCTION
TABLE 4 GLOBAL MARKET, BY SERVICE, 2020–2027 (USD MILLION)
6.2 LOGISTICS AND DISTRIBUTION
6.2.1 EVOLVING TREATMENT PROTOCOLS AND DATA SECURITY CHALLENGES TO DRIVE DEMAND FOR LOGISTICS AND DISTRIBUTION SERVICES
TABLE 5 GLOBAL MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 6 NORTH AMERICA: MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 7 EUROPE: MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 8 ASIA PACIFIC: MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 STORAGE AND RETENTION
6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH
TABLE 9 GLOBAL MARKET FOR STORAGE AND RETENTION SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 10 NORTH AMERICA: MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 EUROPE: MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 12 ASIA PACIFIC: MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 PACKAGING, LABELING, AND BLINDING
6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE MARKET
TABLE 13 GLOBAL MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 NORTH AMERICA: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 ASIA PACIFIC: MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 MANUFACTURING
6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET
TABLE 17 GLOBAL MARKET FOR MANUFACTURING SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 EUROPE: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 ASIA PACIFIC: MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 COMPARATOR SOURCING
6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH
TABLE 21 GLOBAL MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 EUROPE: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 ASIA PACIFIC: MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
6.7 OTHER SERVICES
TABLE 25 GLOBAL MARKET FOR OTHER SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NORTH AMERICA: MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 EUROPE: MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 ASIA PACIFIC: MARKET FOR OTHER SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE (Page No. - 83)
7.1 INTRODUCTION
TABLE 29 GLOBAL MARKET, BY PHASE, 2020–2027 (USD MILLION)
7.2 PHASE III
7.2.1 PHASE III TRIALS INVOLVE LARGE PATIENT POPULATION
TABLE 30 GLOBAL MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 EUROPE: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 ASIA PACIFIC: MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 PHASE II
7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING EFFECTIVENESS OF DRUG AND FURTHER EVALUATING ITS SAFETY
TABLE 34 GLOBAL MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 EUROPE: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 ASIA PACIFIC: MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PHASE I
7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY VITAL ROLE IN PHASE I CLINICAL TRIALS
TABLE 38 GLOBAL MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 ASIA PACIFIC: MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 PHASE IV
7.5.1 PHASE IV STUDIES ALLOW RESEARCHERS TO OBSERVE LONG-TERM EFFECTS OF PARTICULAR DRUGS IN LARGER POOL OF PATIENTS
TABLE 42 GLOBAL MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 ASIA PACIFIC: MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 BA/BE STUDIES
7.6.1 PATENT EXPIRATION OF DRUGS TO INCREASE DEMAND FOR BA/BE STUDIES
TABLE 46 GLOBAL MARKET FOR BA/BE STUDIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 ASIA PACIFIC: MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020–2027 (USD MILLION)
8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE (Page No. - 95)
8.1 INTRODUCTION
TABLE 50 GLOBAL MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2 SMALL-MOLECULE DRUGS
8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET
TABLE 51 GLOBAL MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 NORTH AMERICA: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 EUROPE: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 ASIA PACIFIC: MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 BIOLOGIC DRUGS
8.3.1 BIOLOGIC DRUGS HAVE RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS
TABLE 55 GLOBAL MARKET FOR BIOLOGIC DRUGS, BY REGION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 ASIA PACIFIC: MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 MEDICAL DEVICES
8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO DRIVE MARKET
TABLE 59 GLOBAL MARKET FOR MEDICAL DEVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020–2027 (USD MILLION)
9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA (Page No. - 103)
9.1 INTRODUCTION
TABLE 63 GLOBAL MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
9.2 ONCOLOGY
9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET
TABLE 64 GLOBAL MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CNS AND MENTAL DISORDERS
9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET
TABLE 68 GLOBAL MARKET FOR CNS AND MENTAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 EUROPE: MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 ASIA PACIFIC: MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 CARDIOVASCULAR DISEASES
9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH
TABLE 72 GLOBAL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 DIGESTIVE DISORDERS
9.5.1 INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE MARKET
TABLE 76 GLOBAL MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.6 INFECTIOUS DISEASES
9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 ACCELERATED EFFORTS TO DEVELOP NEW DRUGS
TABLE 80 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
9.7 METABOLIC DISORDERS
9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE GROWTH
TABLE 84 GLOBAL MARKET FOR METABOLIC DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ASIA PACIFIC: MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.8 BLOOD DISORDERS
9.8.1 GROWTH IN NUMBER OF HEMOPHILIA PATIENTS TO BOOST PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS
TABLE 88 GLOBAL MARKET FOR BLOOD DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 ASIA PACIFIC: MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
9.9 IMMUNOLOGY
9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL NEED FOR PROCURING CLINICAL TRIAL SUPPLIES
TABLE 92 GLOBAL MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9.10 OTHER THERAPEUTIC AREAS
TABLE 96 GLOBAL MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 99 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION)
10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER (Page No. - 123)
10.1 INTRODUCTION
TABLE 100 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.2.1 INCREASING R&D INVESTMENTS TO BOOST OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
TABLE 101 GLOBAL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS
TABLE 105 GLOBAL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 106 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 107 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 MEDICAL DEVICE COMPANIES
10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET
TABLE 109 GLOBAL MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 110 NORTH AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 111 EUROPE: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 112 ASIA PACIFIC: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION (Page No. - 131)
11.1 INTRODUCTION
TABLE 113 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
TABLE 114 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 116 NORTH AMERICA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 117 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 119 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing R&D investments to drive market
TABLE 120 US: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 121 US: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 122 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 US: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 124 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth
TABLE 125 CANADA: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 126 CANADA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 127 CANADA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 CANADA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 129 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 130 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 131 EUROPE: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 132 EUROPE: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 133 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 EUROPE: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 135 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies
TABLE 136 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 137 GERMANY: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 138 GERMANY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 GERMANY: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 140 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth
TABLE 141 UK: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 142 UK: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 143 UK: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 UK: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 145 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Presence of leading pharmaceutical companies to support market growth
TABLE 146 FRANCE: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 147 FRANCE: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 148 FRANCE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 FRANCE: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 150 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies
TABLE 151 ITALY: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 152 ITALY: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 153 ITALY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 154 ITALY: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 155 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing biologics production to support market growth
TABLE 156 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 157 SPAIN: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 158 SPAIN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 SPAIN: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 160 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 SWITZERLAND
11.3.6.1 Growing R&D efforts to provide growth opportunities for market
TABLE 161 SWITZERLAND: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 162 SWITZERLAND: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 163 SWITZERLAND: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 SWITZERLAND: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 165 SWITZERLAND: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 166 REST OF EUROPE: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 167 REST OF EUROPE: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 168 REST OF EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 170 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
TABLE 171 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 172 ASIA PACIFIC: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 173 ASIA PACIFIC: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 174 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 175 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 176 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Favorable government regulations to boost market growth
TABLE 177 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 178 CHINA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 179 CHINA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 180 CHINA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 181 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Government initiatives for drug innovation to support market growth
TABLE 182 JAPAN: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 183 JAPAN: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 184 JAPAN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 185 JAPAN: MARKER, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 186 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Low manufacturing costs and skilled workforce—factors attracting outsourcing and investment to India
TABLE 187 INDIA: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 188 INDIA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 189 INDIA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 190 INDIA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 191 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Favorable location for drug discovery due to presence of many research institutes
TABLE 192 AUSTRALIA: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 193 AUSTRALIA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 194 AUSTRALIA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 196 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Seoul among world’s largest clinical research centers
TABLE 197 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 198 SOUTH KOREA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 199 SOUTH KOREA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 200 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 201 SOUTH KOREA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.6 SINGAPORE
11.4.6.1 Presence of world-class infrastructure to drive market
TABLE 202 SINGAPORE: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 203 SINGAPORE: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 204 SINGAPORE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 205 SINGAPORE: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 206 SINGAPORE: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 207 REST OF ASIA PACIFIC: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 208 REST OF ASIA PACIFIC: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 209 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 211 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 212 REST OF THE WORLD: MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 213 REST OF THE WORLD: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 214 REST OF THE WORLD: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 215 REST OF THE WORLD: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 216 REST OF THE WORLD: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 217 REST OF THE WORLD: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 LATIN AMERICA
11.5.1.1 Growing R&D expenditure in pharmaceutical and biopharmaceutical sector to drive market
TABLE 218 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 219 LATIN AMERICA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 220 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 221 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 222 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.2 MIDDLE EAST AND AFRICA
11.5.2.1 Growing presence of pharmaceutical companies to drive market
TABLE 223 MIDDLE EAST AND AFRICA: MARKET, BY SERVICE, 2020–2027 (USD MILLION)
TABLE 224 MIDDLE EAST AND AFRICA: MARKET, BY PHASE, 2020–2027 (USD MILLION)
TABLE 225 MIDDLE EAST AND AFRICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 MIDDLE EAST AND AFRICA: MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION)
TABLE 227 MIDDLE EAST AND AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 201)
12.1 OVERVIEW
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 27 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
FIGURE 28 KEY PLAYERS IN GLOBAL MARKET
12.4 MARKET SHARE ANALYSIS
FIGURE 29 GLOBAL MARKET SHARE, BY KEY PLAYER, 2021
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 30 GLOBAL MARKET: COMPANY EVALUATION QUADRANT, 2021
12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 31 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021
12.7 COMPETITIVE BENCHMARKING
TABLE 228 GLOBAL MARKET: DETAILED LIST OF KEY STARTUPS/SMES
12.7.1 FOOTPRINT ANALYSIS OF COMPANIES
TABLE 229 SERVICE FOOTPRINT OF COMPANIES
TABLE 230 REGIONAL FOOTPRINT OF COMPANIES
12.8 COMPETITIVE SCENARIO
TABLE 231 SERVICE LAUNCHES
TABLE 232 DEALS
TABLE 233 OTHER DEVELOPMENTS
13 COMPANY PROFILES (Page No. - 216)
13.1 MAJOR PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 THERMO FISHER SCIENTIFIC
TABLE 234 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
13.1.2 CATALENT, INC.
TABLE 235 CATALENT, INC.: BUSINESS OVERVIEW
FIGURE 33 CATALENT, INC.: COMPANY SNAPSHOT (2021)
13.1.3 MARKEN (SUBSIDIARY OF UPS)
TABLE 236 UPS: BUSINESS OVERVIEW
FIGURE 34 UPS: COMPANY SNAPSHOT (2021)
13.1.4 EUROFINS SCIENTIFIC
TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 35 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
13.1.5 PRA HEALTH SCIENCES (SUBSIDIARY OF ICON PLC)
TABLE 238 ICON PLC: BUSINESS OVERVIEW
FIGURE 36 ICON PLC: COMPANY SNAPSHOT (2021)
13.1.6 PAREXEL INTERNATIONAL CORPORATION
TABLE 239 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
13.1.7 BIOCAIR
TABLE 240 BIOCAIR: BUSINESS OVERVIEW
13.1.8 ALMAC GROUP
TABLE 241 ALMAC GROUP: BUSINESS OVERVIEW
13.1.9 PIRAMAL PHARMA SOLUTIONS
TABLE 242 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
FIGURE 37 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
13.1.10 INFOSYS
TABLE 243 INFOSYS: BUSINESS OVERVIEW
FIGURE 38 INFOSYS: COMPANY SNAPSHOT (2022)
13.1.11 PCI PHARMA SERVICES
TABLE 244 PCI PHARMA SERVICES: BUSINESS OVERVIEW
13.1.12 LIVEO RESEARCH
TABLE 245 LIVEO RESEARCH: BUSINESS OVERVIEW
13.1.13 CAPSUGEL (ACQUIRED BY LONZA)
TABLE 246 LONZA: BUSINESS OVERVIEW
FIGURE 39 LONZA: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 OCT GROUP LLC
13.2.2 COREX LOGISTICS
13.2.3 ACNOS PHARMA GMBH
13.2.4 CLINICAL SERVICES INTERNATIONAL
13.2.5 KLIFO
13.2.6 CLINIGEN LIMITED
13.2.7 ANCILLARE, LP
13.2.8 N-SIDE
13.2.9 ADALLEN PHARMA
13.2.10 DURBIN
13.2.11 RECIPHARM AB
13.2.12 MOVIANTO
14 APPENDIX (Page No. - 257)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global clinical trial supplies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The market size was estimated through various secondary research approaches and triangulated with inputs from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources [such as the World Bank, World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC)]; sites like ClinicalTrials.gov, fiercebiotech, and annual reports; SEC filings; press releases; investor presentations; journals; expert interviews; MarketsandMarkets analysis; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.
Primary Research
After acquiring basic knowledge about the global market scenario through secondary research, extensive primary research was conducted. Several primary interviews were conducted with market experts from both the demand side (such as personnel from pharmaceutical & biotechnology companies) and the supply side (such as clinical trial supply companies and pharmaceutical supply companies) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the clinical trial supplies market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the clinical trial supplies business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global clinical trial supplies market based on type, therapeutic area, service, end user, phase, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, and opportunities)
- To forecast the size of the market segments with respect to four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key market players and comprehensively analyze their service portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, service launches, expansions, partnerships, collaborations in the market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Growth opportunities and latent adjacency in Clinical Trial Supplies Market
What are the major growth strategies prevalent in the Clinical Trial Supplies Market?
Which factors are influencing the global growth of Clinical Trial Supplies Market?
Which are the different geographies covered in the global study of Clinical Trial Supplies Market?